Company profile for Congruence

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Congruence Therapeutics is a pioneering biotechnology company leveraging advanced computational approaches to transform drug discovery. By integrating protein dynamics, biophysics, and machine learning, we identify and develop innovative therapeutics for challenging diseases. Our focus is on uncovering novel, disease-modifying therapies that address unmet medical needs. At Congruence, we are driven by scientific excellence and...
Congruence Therapeutics is a pioneering biotechnology company leveraging advanced computational approaches to transform drug discovery. By integrating protein dynamics, biophysics, and machine learning, we identify and develop innovative therapeutics for challenging diseases. Our focus is on uncovering novel, disease-modifying therapies that address unmet medical needs. At Congruence, we are driven by scientific excellence and a commitment to improving patient outcomes. Through cutting-edge technology and a passion for innovation, we aim to make a lasting impact on healthcare.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Canada
Address
Address
7171 Rue Frederick-Banting, 117 Montreal, Quebec, H4S 1Z9
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/congruence-therapeutics-to-present-preclinical-characterization-of-its-mc4r-corrector-development-candidate-cgx-926-for-genetic-obesity-at-obesityweek-2025-302607289.html

PR NEWSWIRE
06 Nov 2025

https://www.prnewswire.com/news-releases/congruence-awarded-grant-from-the-michael-j-fox-foundation-for-parkinsons-research-mjff-to-advance-novel-gcase-activators-and-correctors-for-parkinsons-disease-with-gba1-mutations-302513139.html

PR NEWSWIRE
24 Jul 2025

https://www.prnewswire.com/news-releases/congruence-therapeutics-announces-oral-presentation-on-mc4r-corrector-development-candidate-cgx-926-for-early-onset-obesity-at-the-3rd-annual-obesity--weight-loss-drug-development-summit-302506056.html

PR NEWSWIRE
16 Jul 2025

https://www.prnewswire.com/news-releases/ono-enters-into-drug-discovery-collaboration-agreement-with-congruence-therapeutics-to-generate-novel-small-molecule-correctors-in-the-oncology-area-302324452.html

PR NEWSWIRE
05 Dec 2024

https://www.prnewswire.com/news-releases/congruence-and-ono-announce-multi-target-research-collaboration-to-generate-small-molecule-correctors-for-the-treatment-of-cancer-302319807.html

PR NEWSWIRE
03 Dec 2024

https://www.prnewswire.com/news-releases/congruence-therapeutics-appoints-experienced-drug-developer-michael-d-harvey-phd-as-chief-development-officer-302136432.html

PR NEWSWIRE
06 May 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty